Gene expression profiling in peripheral blood mononuclear cells from lupus patients with active and inactive disease

被引:32
作者
Rus, V
Chen, HG
Zernetkina, V
Magder, LS
Mathai, S
Hochberg, MC
Via, CS
机构
[1] Univ Maryland, Sch Med, Dept Med, Div Rheumatol & Clin Immunol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Div Biostat & Bioinformat, Baltimore, MD 21201 USA
关键词
systemic lupus eythematosus; disease activity; cDNA array;
D O I
10.1016/j.clim.2004.06.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Systemic lupus erythematosus (SLE) is characterized by periods of flare and remission. The search for parameters associated with disease activity has been an area of intense investigation. To identify genes that best differentiate patients with active from those with inactive disease, the expression pattern of 375 genes was analyzed in peripheral blood mononuclear cells (PBMC) from 12 patients with active and 14 patients with inactive disease. Using the "nearest shrunken centroids" method, 29 genes were found to best discriminate the two groups. Among these genes, 14 were upregulated and 15 were downregulated in patients with active compared to those with inactive disease. Fourteen of these genes also correlated with SELENA-SLEDAI with correlation coefficients ranging from 0.4 to 0.7. Most of these genes have not been previously associated with disease activity and belong to a variety of families such as adhesion molecules, proteases, TNF superfamily, and neurotrophic factors. Using a cross-validation method, the error rate for classifying samples in the two groups was 30%. These results highlight the potential use of microarray data in identifying genes associated with disease activity in SLE, which could become potential biomarkers or future therapeutic targets. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:231 / 234
页数:4
相关论文
共 16 条
  • [1] Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
    Baechler, EC
    Batliwalla, FM
    Karypis, G
    Gaffney, PM
    Ortmann, WA
    Espe, KJ
    Shark, KB
    Grande, WJ
    Hughes, KM
    Kapur, V
    Gregersen, PK
    Behrens, TW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) : 2610 - 2615
  • [2] Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
    Bennett, L
    Palucka, AK
    Arce, E
    Cantrell, V
    Borvak, J
    Banchereau, J
    Pascual, V
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (06) : 711 - 723
  • [3] DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS
    BOMBARDIER, C
    GLADMAN, DD
    UROWITZ, MB
    CARON, D
    CHANG, CH
    [J]. ARTHRITIS AND RHEUMATISM, 1992, 35 (06): : 630 - 640
  • [4] Interferon-α:: A new target for therapy in systemic lupus erythematosus?
    Crow, MK
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : 2396 - 2401
  • [5] Crow MK, 2002, ARTHRITIS RHEUM-US, V46, pS281
  • [6] DUDOIT S, 2002, UNDERSTANDING USING, P93
  • [7] Cluster analysis and display of genome-wide expression patterns
    Eisen, MB
    Spellman, PT
    Brown, PO
    Botstein, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) : 14863 - 14868
  • [8] Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus - Why some tests fail
    Esdaile, JM
    Abrahamowicz, M
    Joseph, L
    MacKenzie, T
    Li, Y
    Danoff, D
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (03): : 370 - 378
  • [9] Increased serum levels of soluble L-selectin (CD62L) in patients with active systemic lupus erythematosus (SLE)
    Font, J
    Pizcueta, P
    Ramos-Casals, M
    Cervera, R
    García-Carrasco, M
    Navarro, M
    Ingelmo, M
    Engel, P
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 119 (01) : 169 - 174
  • [10] NEWTON RC, 2001, ANN RHEUM DIS S3, V60, P25